Erythropoietin Receptor Expression and Correlation to Tamoxifen Response and Prognosis in Breast Cancer.
Larsson, Anna-Maria LU ; Jirström, Karin LU
; Fredlund, Erik
LU
; Björner, Sofie
LU
; Rydén, Lisa
LU
; Landberg, Göran
LU
and Påhlman, Sven
LU
(2009)
In Clinical Cancer Research
15(17).
p.5552-5559
- Abstract
- PURPOSE: The main function of erythropoietin (EPO) is to stimulate erythropoiesis. EPO receptors (EPOR) are expressed in other cell types, including tumor cells, suggesting that the EPO/EPOR pathway governs additional cellular processes besides erythropoiesis. Recombinant EPO (rhEPO) is frequently given to anemic cancer patients, although data on clinical outcome are conflicting. In an attempt to understand these clinical data, we analyzed EPO and EPOR expression in breast cancer and evaluated EPOR as a putative prognostic and predictive marker in breast cancer patients treated with tamoxifen. EXPERIMENTAL DESIGN: EPO mRNA/protein and EPOR mRNA were quantified by PCR and ELISA, respectively. Tissue microarrays containing 500 breast tumors... (More)
- PURPOSE: The main function of erythropoietin (EPO) is to stimulate erythropoiesis. EPO receptors (EPOR) are expressed in other cell types, including tumor cells, suggesting that the EPO/EPOR pathway governs additional cellular processes besides erythropoiesis. Recombinant EPO (rhEPO) is frequently given to anemic cancer patients, although data on clinical outcome are conflicting. In an attempt to understand these clinical data, we analyzed EPO and EPOR expression in breast cancer and evaluated EPOR as a putative prognostic and predictive marker in breast cancer patients treated with tamoxifen. EXPERIMENTAL DESIGN: EPO mRNA/protein and EPOR mRNA were quantified by PCR and ELISA, respectively. Tissue microarrays containing 500 breast tumors from premenopausal women randomized to tamoxifen or no adjuvant treatment were evaluated for EPOR expression by immunohistochemistry. Predictive and prognostic information was evaluated using Kaplan-Meier curves and log-rank tests to estimate recurrence-free survival (RFS). RESULTS: EPO and EPOR were expressed in cultured cells, and breast tumor specimens expressed EPOR at varying levels. Tamoxifen treatment significantly increased RFS in patients with estrogen receptor-positive/progesterone receptor-positive (ER(+)/PR(+)) tumors with low EPOR expression (P = 0.001) but had no effect on RFS in patients with tumors with high EPOR expression (P = 0.98). In the untreated cohort, RFS was significantly improved for patients with ER(+) tumors with high EPOR expression. CONCLUSION: EPOR is abundantly expressed in breast cancer specimens. The fact that high expression of EPOR is related to an impaired tamoxifen response in ER(+)/PR(+) tumors and to improved survival in untreated patients suggests that EPOR expression in breast cancer affects tumor behavior. (Clin Cancer Res 2009;15(17):5552-9). (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1469363
- author
- Larsson, Anna-Maria
LU
; Jirström, Karin
LU
; Fredlund, Erik
LU
; Björner, Sofie
LU
; Rydén, Lisa
LU
; Landberg, Göran
LU
and Påhlman, Sven
LU
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Clinical Cancer Research
- volume
- 15
- issue
- 17
- pages
- 5552 - 5559
- publisher
- American Association for Cancer Research
- external identifiers
-
- wos:000269565800032
- pmid:19706814
- scopus:69949089786
- ISSN
- 1078-0432
- DOI
- 10.1158/1078-0432.CCR-08-3014
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Pathology (Malmö) (013031000), Surgery (Lund) (013009000), Molecular Medicine (013031200), Pathology, (Lund) (013030000)
- id
- 17e57a59-b2ee-43d8-956f-16b03bcb9442 (old id 1469363)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19706814?dopt=Abstract
- date added to LUP
- 2016-04-04 08:23:31
- date last changed
- 2024-01-29 02:52:40
@article{17e57a59-b2ee-43d8-956f-16b03bcb9442,
abstract = {{PURPOSE: The main function of erythropoietin (EPO) is to stimulate erythropoiesis. EPO receptors (EPOR) are expressed in other cell types, including tumor cells, suggesting that the EPO/EPOR pathway governs additional cellular processes besides erythropoiesis. Recombinant EPO (rhEPO) is frequently given to anemic cancer patients, although data on clinical outcome are conflicting. In an attempt to understand these clinical data, we analyzed EPO and EPOR expression in breast cancer and evaluated EPOR as a putative prognostic and predictive marker in breast cancer patients treated with tamoxifen. EXPERIMENTAL DESIGN: EPO mRNA/protein and EPOR mRNA were quantified by PCR and ELISA, respectively. Tissue microarrays containing 500 breast tumors from premenopausal women randomized to tamoxifen or no adjuvant treatment were evaluated for EPOR expression by immunohistochemistry. Predictive and prognostic information was evaluated using Kaplan-Meier curves and log-rank tests to estimate recurrence-free survival (RFS). RESULTS: EPO and EPOR were expressed in cultured cells, and breast tumor specimens expressed EPOR at varying levels. Tamoxifen treatment significantly increased RFS in patients with estrogen receptor-positive/progesterone receptor-positive (ER(+)/PR(+)) tumors with low EPOR expression (P = 0.001) but had no effect on RFS in patients with tumors with high EPOR expression (P = 0.98). In the untreated cohort, RFS was significantly improved for patients with ER(+) tumors with high EPOR expression. CONCLUSION: EPOR is abundantly expressed in breast cancer specimens. The fact that high expression of EPOR is related to an impaired tamoxifen response in ER(+)/PR(+) tumors and to improved survival in untreated patients suggests that EPOR expression in breast cancer affects tumor behavior. (Clin Cancer Res 2009;15(17):5552-9).}},
author = {{Larsson, Anna-Maria and Jirström, Karin and Fredlund, Erik and Björner, Sofie and Rydén, Lisa and Landberg, Göran and Påhlman, Sven}},
issn = {{1078-0432}},
language = {{eng}},
number = {{17}},
pages = {{5552--5559}},
publisher = {{American Association for Cancer Research}},
series = {{Clinical Cancer Research}},
title = {{Erythropoietin Receptor Expression and Correlation to Tamoxifen Response and Prognosis in Breast Cancer.}},
url = {{http://dx.doi.org/10.1158/1078-0432.CCR-08-3014}},
doi = {{10.1158/1078-0432.CCR-08-3014}},
volume = {{15}},
year = {{2009}},
}